
Opinion|Videos|July 30, 2024
Impact of BCG Therapy Shortage on the Management of High-Risk NMIBC
Trinity Bivalacqua, MD, PhD and Mark Tyson, MD, MPH discuss the current shortage of BCG therapy and how that has impacted clinical practice management.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Can you describe the current shortage of bacillus Calmette-Guerin, or BCG, therapy; how has this has impacted your clinical practice and management of high-risk NMIBC?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Team-based AE protocols improve consistency with the gemcitabine intravesical therapy system
2
Practical tips for AE management with the gemcitabine intravesical system
3
Jamie Michael, MD, discusses MRI and genomics in active surveillance
4
Richard Schlussel, MD, highlights emerging technologies in pediatric urology
5












